Literature DB >> 11549802

Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.

M C Brouard1, C Prins, S Mach-Pascual, J H Saurat.   

Abstract

The tyrosine kinase inhibitor STI571 is a novel promising class of anticancer drugs. We report a case of cutaneous adverse reactions to STI571 in a young woman with blast crisis of chronic myeloid leukemia. She had first typical acute generalized exanthematous pustulosis mimicking mercury rash and then urticarial eruption. We suggest that cell pathways mediated by some tyrosine kinases might be involved in the pathogenesis of these skin eruptions. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11549802     DOI： 10.1159/000051705

Source DB:  PubMed          Journal:  Dermatology        ISSN： 1018-8665            Impact factor:   5.366


  10 in total

1.  BCR-ABL kinase is dead; long live the CML stem cell.

Authors:  Alexander Perl; Martin Carroll
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

2.  Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia.

Authors:  Murat Albayrak; Harika Celebi; Aynur Albayrak; Esra Saribacak Can; Vedat Aslan; Birgul Onec; Ipek Coban
Journal:  Eurasian J Med       Date:  2011-12

Review 3.  Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase.

Authors:  Vito Michele Lauta
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 4.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

5.  Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).

Authors:  Ah Young Cho; Dae Hun Kim; Myung Im; Young Lee; Young Joon Seo; Jeung Hoon Lee
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

6.  Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.

Authors:  Caterina Musolino; Alessandro Allegra; Carmen Mannucci; Sabina Russo; Andrea Alonci; Valerio Maisano; Gioacchino Calapai; Sebastiano Gangemi
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

Review 7.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

Review 8.  IL-31, itch and hematological malignancies.

Authors:  Eleonora Di Salvo; Alessandro Allegra; Marco Casciaro; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2021-06-12

9.  Lapatinib-induced acute generalized exanthematous pustulosis.

Authors:  Chembolli Lakshmi; Suma Pillai; C R Srinivas
Journal:  Indian Dermatol Online J       Date:  2010-07

Review 10.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.